EN DE
Watch Perspective Therapeutics Inc. for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Perspective Therapeutics Inc. (CATX) fair value: what the stock is really worth

As of Nov 9, 2026: fair value (intrinsic value) of Perspective Therapeutics Inc. stock $0.61, price $0.86, that is 28.9% below the price, quality 27 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

PT Perspective Therapeutics Inc. logo Thin data Nov 10, 2026

Perspective Therapeutics Inc.

CATX · US
Expensive, weak quality

Our calculation puts a fair price 29% below what the stock costs today.

Low debt
Revenue last quarter 72% below a year ago.
Fair value $0.6086 · Overvalued
Quality 27/100
Weak Growth (revenue 5y −38.0 %/yr in USD)
Negative free cash flow
Trails peers (2/7)
Narrow moat 5/100 · thin data
Thin data
Estimate
Watch Perspective Therapeutics Inc. for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$18.40 $0.7884 Fair Value $0.6086 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range $0.7884 – $18.40 · fair‑value band $0.4565 – $0.7608 · the $0.8556 price screens above the $0.6086 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 2 fiscal years are left out: there the valuation rested on only a fraction of the usual models. As of Nov 10, 2026.

Follow Perspective Therapeutics in your weekly email

Every Wednesday you see whether Perspective Therapeutics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States.

Show moreShow less

It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma; and PSV359, a targeted alpha therapy targeting fibroblast activation protein alpha.

The company also develops Pluvicto, a betaemitting radioligand therapy to treat progressive prostate-specific membrane antigen (PSMA) positive metastatic castration-resistant prostate cancer.

It has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans.

The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 2004 and is headquartered in Seattle, Washington.

Stock analysis

Perspective Therapeutics Inc. (CATX) currently trades at $0.8556, while our estimate is $0.6086, 29% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $0.4565 (bear) to $0.7608 (bull), the price of $0.8556 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 27/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Perspective Therapeutics Inc. reported revenue of $884K in FY2025 versus $10.1M in FY2021, a compound −45.5%/yr. Reported net income was −$103M in FY2025.

Key figures

Market cap $97.7M Micro · EPS (TTM) $−1.35 · Return on equity −39.6% · Return on assets (EBIT) −16.4% (5-year average) · Operating margin −36,121% · Revenue (TTM) $409K · Revenue growth (YoY) −72.1% · Free cash flow −$95.2M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 5 out of 100 (low confidence).

What moves the price

The share trades about 85% below its 52-week high and 9% above its 52-week low.

For context, the median of 10 Healthcare peers we cover trades at 9% fair-value upside, at −29%, CATX screens richer than that median.

Fair Value

Bear $0.4565 Fair Value $0.6086 Bull $0.7608
Price $0.8556 · Downside -28.9%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 27/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 10
Are margins and returns getting better?
Cashflow 7
Do the profits arrive as real cash?
Financial strength 60
Debt, balance sheet and risk of trouble
Investment 0
Does it invest with discipline instead of growing at any price?
Low Volatility 0
How calm the share price moves, does not count
Price momentum 13
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 1
Distance to the 52-week high, does not count
New shares 90
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, no officer or director bought or sold shares on the open market.

  • SaleLantheus Alpha Therapy, LLC10% owner2× since Aug 31, 2026: 361,846 shares, avg. $3.14$1.1MSep 4, 2026
  • SaleLantheus Holdings, Inc.10% owner3× since Aug 31, 2026: 156,043 shares, avg. $3.13$487,996Sep 2, 2026
  • BuyJonathan Robert HuntChief Accounting Officer11,000 shares at $2.03$22,330Nov 13, 2025
  • BuyRobert F Williamson IIIDirector9,498 shares at $2.10$19,946Nov 12, 2025

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 9, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−39.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−56.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−38.0%
Start year 2020 (pandemic). Over 10 years: −15.2% a year
Revenue growth 31 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−6.4%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−35.9% (2020) → −12,846.6% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

CATX screens overvalued: fair value 29% below the price. Compare with Abbott Laboratories, →

Compare Perspective Therapeutics Inc. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 400 stocks

Beats the industry median on 2/6 measures
Overall it trails its industry peers.
Valuation
Quality Score 27 · Bottom 25%
Fair Value upside −28.9% · Below median
Profitability
Return on assets −38.6% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −72.1% · Bottom 25%
Balance sheet
Debt / equity 0.01× · Below median

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/B 0.47× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 16
FUTURE (revenue growth)0 · sector 43
PAST (return on equity)0 · sector 0
HEALTH (low debt)100 · sector 97
DIVIDEND (yield)0 · sector 34

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥181.10 ¥202.57 +12% vs CATX
Stryker Corporation SYK $325.73 $358.46 +10% vs CATX
Boston Scientific Corporation BSX $44.02 $48.42 +10% vs CATX
DexCom, Inc DXCM $81.07 $89.18 +10% vs CATX
STERIS plc STE $256.94 $279.53 +9% vs CATX
GE HealthCare Technologies Inc GEHC $84.03 $69.92 −17% vs CATX
Edwards Lifesciences Corporation EW $104.71 $81.94 −22% vs CATX
Abbott Laboratories, ABT $110.51 $75.28 −32% vs CATX
Medtronic plc MDT $102.79 $65.61 −36% vs CATX
Koninklijke Philips N.V PHIA €27.30 €15.23 −44% vs CATX

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Perspective Therapeutics Inc.: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Perspective Therapeutics Inc. Fair Value". https://www.fairvalue-calculator.com/stock/CATX

Frequently asked questions

Is Perspective Therapeutics Inc. (CATX) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is $0.6086 versus a price of $0.8556, about 29% lower (overvalued).
What is the fair value of CATX?
Our estimate for Perspective Therapeutics Inc. is $0.6086 (as of Nov 10, 2026), built from audited fundamentals. The current price: $0.8556.
What is the quality score of CATX?
Perspective Therapeutics Inc. has a Quality Score of 27/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Perspective Therapeutics Inc. (CATX)?
Our calculated price target is the estimate of $0.6086 (as of Nov 10, 2026). Cautious scenario $0.4565, optimistic scenario $0.7608. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Perspective Therapeutics Inc. stock forecast for 2026?
Our estimate puts fair value at $0.6086, about 29% lower versus a price of $0.8556 (overvalued). Cautious scenario $0.4565, optimistic scenario $0.7608. The calculation is refreshed regularly with new filings.
What is the revenue of Perspective Therapeutics Inc. (CATX)?
Perspective Therapeutics Inc. reported trailing-twelve-month revenue of about $409K (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Perspective Therapeutics Inc. (CATX)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Perspective Therapeutics Inc. it is $0.6086 per share (as of Nov 10, 2026), against a price of $0.8556.
Is Perspective Therapeutics Inc. stock overvalued or undervalued in 2026?
As of Nov 10, 2026, CATX trades above its calculated fair value: price $0.8556, fair value $0.6086, a gap of about −29% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CATX?
No. The price is what the market pays today ($0.8556); the fair value is what the company's own numbers justify ($0.6086). For Perspective Therapeutics Inc. the two are $0.2470 per share apart. That gap is exactly why we show both numbers side by side.
How much is Perspective Therapeutics Inc. worth?
The market values Perspective Therapeutics Inc. at about $97.7M (market capitalisation, as of Nov 10, 2026). Per share that is $0.8556; our models calculate a fair value of $0.6086 per share.
What do the bullish and bearish scenarios say about CATX?
Our models span a range for Perspective Therapeutics Inc.: cautious scenario $0.4565, base $0.6086, optimistic $0.7608 per share (as of Nov 10, 2026, price $0.8556). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Perspective Therapeutics Inc. (CATX)?
Balance-sheet figures for Perspective Therapeutics Inc. (as of Nov 10, 2026): return on equity −39.6%, debt of 0.01 per unit of equity. They feed the Quality Score of 27/100, which measures business quality independently of the share price.
How far is CATX from its 52-week high?
Perspective Therapeutics Inc. trades at $0.8556, about 85% below its 52-week high of $5.65 and 9% above the low of $0.7884 (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of $0.6086 is for.
Which stocks are comparable to Perspective Therapeutics Inc.?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Perspective Therapeutics Inc. stock attractive at the current price?
The data as of Nov 10, 2026: price $0.8556, calculated fair value $0.6086 (−29%), Quality Score 27/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 13.7% above its aggregate fair value. Perspective Therapeutics Inc. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Perspective Therapeutics Inc. (CATX)?
The closing price on Nov 9, 2026 was $0.8556. Our estimate is $0.6086, about 29% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Perspective Therapeutics Inc. right now?
The price sits above even our optimistic bull case ($0.7608). The favourable scenario is already priced in. Weak quality (27/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Perspective Therapeutics Inc.

How large is the market capitalisation of Perspective Therapeutics Inc. (CATX)?
The market capitalisation of Perspective Therapeutics Inc. is $97.7M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Perspective Therapeutics Inc. (CATX)?
Earnings per share at Perspective Therapeutics Inc. are $−1.35. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Perspective Therapeutics Inc. (CATX)?
The return on equity (ROE) of Perspective Therapeutics Inc. is −39.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Perspective Therapeutics Inc. (CATX)?
On an EBIT basis the return on assets of Perspective Therapeutics Inc. is −16.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Perspective Therapeutics Inc. (CATX)?
The operating margin of Perspective Therapeutics Inc. is −36,121% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Perspective Therapeutics Inc. (CATX)?
Revenue at Perspective Therapeutics Inc. is growing −72.1% versus a year earlier (3y avg −56.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Perspective Therapeutics Inc. (CATX) generate?
The free cash flow of Perspective Therapeutics Inc. is −$95.2M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Perspective Therapeutics Inc. (CATX) hold?
Perspective Therapeutics Inc. holds more cash than debt, $29.0M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Perspective Therapeutics Inc. in the live analysis

One click puts Perspective Therapeutics Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.